Phase II clinical trial with long-term infusion of anti-GD2 antibody ch14.18/CHO in combination with interleukin-2 (IL2) in patients with high risk neuroblastoma.

被引：0
|
作者：
Lode, Holger N.
Valteau-Couanet, Dominique
Troschke-Meurer, Sascha
Manzitti, Carla
Gray, Juliet
Castel, Victoria
Yaniv, Isaac
Loibner, Hans
Siebert, Nikolai
Glogova, Evgenia
Poetschger, Ulrike
Ladenstein, Ruth
机构：
[1] Univ Med Greifswald, Greifswald, Germany
[2] Univ Paris Sud, Inst Gustave Roussy, Pediat & Adolescent Oncol, Villejuif, France
[3] Gaslini Inst, Genoa, Italy
[4] Univ Southampton, Southampten, England
[5] Pediat Oncol Unit Hosp La Fe Valencia, Pediat Hematol & Oncol, Valencia, Spain
[6] Schneider Childrens Med Ctr Israel, Pediat Hematol Oncol, Petah Tiqwa, Israel
[7] Apeiron Biol AG, Vienna, Austria
[8] St Anna Kinderkrebsforschung eV, Vienna, Austria
[9] St Anna Childrens Canc Res Inst, Vienna, Austria
[10] St Anna Childrens Hosp & Res Inst, Paediat Haematol Oncol, SIOP Europe Neuroblastoma Grp, Vienna, Austria
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2016年 / 34卷 / 15期
关键词：
D O I：
10.1200/JCO.2016.34.15_suppl.10562
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
10562
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Association of regulatory- and helper-T-cells with inferior survival of neuroblastoma patients treated with long-term infusion of ch14.18/CHO combined with interleukin-2.
    Lode, Holger N.
    Troschke-Meurer, Sascha
    Marx, Madlen
    Zumpe, Maxi
    Ehlert, Karoline
    Loibner, Hans
    Ladenstein, Ruth Lydia
    Siebert, Nikolai
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [42] Characterization and partial sequencing of a human anti-idiotypic antibody against anti-GD2 chimeric antibody CH14.18 from a patient treated for neuroblastoma
    Uttenreuther-Fischer, MM
    Neveling, N
    Yu, A
    Gaedicke, G
    Fischer, P
    EUROPEAN JOURNAL OF CANCER, 1999, 35 : S56 - S56
  • [43] SINGLE AGENT ACTIVITY OF THE ANTI-GD2 ANTIBODY DINUTUXIMAB BETA LONG-TERM INFUSION IN HIGH-RISK NEUROBLASTOMA PATIENTS WITH RELAPSED AND REFRACTORY DISEASE. A MULTICENTER PHASE II TRIAL
    Lode, Holger
    Ehlert, Karoline
    Huber, Stephanie
    Siebert, Nikolai
    Troschke-Meurer, Sascha
    Zumpe, Maxi
    Loibner, Hans
    Ladenstein, Ruth
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [44] ANTI-GD2 IMMUNOTHERAPY WITH G-CSF AND INTERLEUKIN-2 FOR HIGH-RISK NEUROBLASTOMA
    Honda, Mamoru
    Arakawa, Yuki
    Kaneko, Ryota
    Kubota, Hirohito
    Mitani, Yuichi
    Mori, Makiko
    Fukuoka, Kohei
    Oshima, Koichi
    Isshiki, Kyohei
    Koh, Katsuyoshi
    PEDIATRIC BLOOD & CANCER, 2022, 69
  • [45] Necrotizing Enterocolitis as an Adverse Effect of Recombinant Interleukin-2 and Ch14.18 in Maintenance Therapy for High-risk Neuroblastoma
    Levy, Gabriel
    Bonnevalle, Michel
    Rocourt, Nathalie
    Sudour, Helene
    Defachelles, Anne-Sophie
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2015, 37 (04) : E250 - E252
  • [46] Randomized use of anti-GD2 antibody dinutuximab beta (DB) long-term infusion with and without subcutaneous interleukin-2 (sclL-2) in high-risk neuroblastoma patients with relapsed and refractory disease: Results from the SIOPEN LTI-trial.
    Lode, Holger N.
    Valteau-Couanet, Dominique
    Gray, Juliet
    Luksch, Roberto
    Wieczorek, Aleksandra
    Castel, Victoria
    Ash, Shifra
    Laureys, Genevieve
    Papadakis, Vassilios
    Owens, Cormac
    Garaventa, Alberto
    Manzitti, Carla
    Siebert, Nikolai
    Troschke-Meurer, Sascha
    Glogova, Evgenia
    Poetschger, Ulrike
    Ladenstein, Ruth Lydia
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [47] A PHASE-I STUDY OF HUMAN MOUSE CHIMERIC ANTIGANGLIOSIDE GD2 ANTIBODY CH14.18 IN PATIENTS WITH NEUROBLASTOMA
    HANDGRETINGER, R
    ANDERSON, K
    LANG, P
    DOPFER, R
    KLINGEBIEL, T
    SCHRAPPE, M
    REULAND, P
    GILLIES, SD
    REISFELD, RA
    NIETHAMMER, D
    EUROPEAN JOURNAL OF CANCER, 1995, 31A (02) : 261 - 267
  • [48] Phase I/II trial in disseminated melanoma with anti-GD2 monoclonal antibody - Monotherapy, in combination with GM-CSF and interleukin-2 fusion protein
    Fierlbeck, G
    Handgretinger, R
    Rassner, G
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1999, 113 (03) : 485 - 485
  • [49] Preliminary results of a phase II study using ch14.18/CHO antibody and interleukin 2 after haplo-identical stem cell transplantation in children with relapsed neuroblastoma
    Lang, P.
    Ladenstein, R.
    Lode, H.
    Teltschik, H. -M.
    Pfeiffer, M.
    Mueller, I.
    Feuchtinger, T.
    Urban, C.
    Bader, P.
    Albert, M.
    Schuster, F.
    Dilloo, D.
    Handgretinger, R.
    BONE MARROW TRANSPLANTATION, 2011, 46 : S135 - S135
  • [50] The anti-GD2 monoclonal antibody naxitamab plus GM-CSF for relapsed or refractory high-risk neuroblastoma: a phase 2 clinical trial
    Mora, Jaume
    Chan, Godfrey C. F.
    Morgenstern, Daniel A.
    Amoroso, Loredana
    Nysom, Karsten
    Faber, Joerg
    Wingerter, Arthur
    Bear, Melissa K.
    Rubio-San-Simon, Alba
    de las Heras, Blanca Martinez
    Tornoe, Karen
    Duering, Maria
    Kushner, Brian H.
    NATURE COMMUNICATIONS, 2025, 16 (01)
12345